AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT03133234
- Locations
- 🇨🇳
Kiang Wu Hospital, Macau, China
Realize the Current Situation of COPD Patients in China
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease COPD
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5020
- Registration Number
- NCT03131362
- Locations
- 🇨🇳
Research Site, Beijing, China
ZS Ph2/3 Dose-response Study in Japan
Phase 2
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (ZS) 5gDrug: Sodium Zirconium Cyclosilicate (ZS) 10gDrug: Placebo
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT03127644
- Locations
- 🇯🇵
Research Site, Yotsukaido-shi, Japan
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
Phase 1
Completed
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT03126695
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Phase 2
Completed
- Conditions
- HyperuricemiaAlbuminuriaType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03118739
- Locations
- 🇺🇸
Research Site, Webster, Texas, United States
Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population
Completed
- Conditions
- Gastrointestinal Disease
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90895
- Registration Number
- NCT03118778
- Locations
- 🇨🇳
Research Site, Beijing, China
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Phase 3
Completed
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT03106987
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
Phase 1
Completed
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid Tumours
- Interventions
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT03101839
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT03097380
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Savolitinib vs. Sunitinib in MET-driven PRCC.
Phase 3
Active, not recruiting
- Conditions
- Protein Kinase InhibitorsCarcinomaCarcinoma, Renal CellEnzyme InhibitorsUrologic NeoplasmsKidney DiseasesKidney NeoplasmsNeoplasms by Site
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03091192
- Locations
- 🇺🇦
Research Site, Sumy, Ukraine
© Copyright 2025. All Rights Reserved by MedPath